In this public lecture, Anthony McDonnell, Policy Fellow at the Centre for Global Development, will discuss the economic burden of AMR. His discussant will be Dr Michael Anderson, Visiting Senior Fellow at LSE Health and Lecturer at the University of Manchester. 

We’ve long known that antibiotics failing due to antimicrobial resistance (AMR) could have a devastating effect on health care, and by extension this would impact the wider economy. Anthony McDonnell led a recent research project for the Center for Global Development, that will be the first global study to publish the national level estimates for the global burden of AMR. This was done using the latest disease burden estimates from the Institute of Health Metrics and Evaluation. CGD’s work is also the first study to model the future cost of AMR on health care systems at the national level, this study also looks at how AMR might impact tourism and hospitality. McDonnell will outline the research methodology in this talk and look in detail at some of the results.

Meet our speakers and chair

Speaker: Anthony McDonnell is a policy fellow in CGD’s global health policy team. He leads CGD’s work on antimicrobial resistance (AMR), including modelling the macro-economic burden of AMR and was previously the technical lead of CGD’s working group, A New Grand Bargain to Improve the Antimicrobial Market for Human Health. He has also led projects analysing the COVID-19 vaccine portfolio, examining policy interventions to protect the supply chains for pharmaceuticals from COVID-19-induced shocks, and contributed to the international Decision Support Initiative’s work in Ethiopia.

Discussant: Dr Michael Anderson is a Senior Visiting Fellow at LSE Health, London School of Economics and Political Science (LSE) and National Institute for Health Research (NIHR) funded Clinical Lecturer at the University of Manchester. He is a general practitioner and continues to practice two days a week in North Yorkshire. He has a PhD in Health Policy and Economics from the London School of Economics and Political Science (LSE) focused on measures of healthcare quality in public and private hospitals in England, and has been awarded a distinction in a joint masters in Health Policy, Planning & Financing from LSE and the London School for Hygiene and Tropical Medicine (LSHTM). 

Chair: Professor Elias Mossialos is Cheng Yu Tung Chair in Global Health and Director of LSE Health. He was the founding Head of the Department of Health Policy. His primary research focus revolves around health systems and policy, with a particular emphasis on issues related to healthcare financing, accessibility, quality, regulation, pharmaceutical policies, AMR, and cancer care and policy. He has developed the Options Market for Antibiotics, an incentive scheme to stimulate research and development (R&D).